BioSpace News Archive

Oncotelic Therapeutics, Inc. (“Oncotelic” or the “Company”) (OTCQB:OTLC), today announced that it has submitted a clinical study protocol to the United States Food and Drug Administration (“US FDA”) for the initiation of a Phase 1 Clinical Trial for CA4P, the Company’s Vascular Disrupting Agent, in combination with Anti-PD-1 (pembrolizumab) as a treatment for patients with Melanoma.

Lipocine Inc. announced that one abstract has been selected for podium presentation and three abstracts have been selected for poster presentations during the upcoming 2022 NASH-TAG Conference in Park City, Utah on January 6-8, 2022.

Haemonetics Corporation announced that the Company intends to publish third quarter fiscal year 2022 financial results at 6:00 am EST on Tuesday, February 8, 2022.

Elevation Oncology, Inc. (Nasdaq: ELEV), today announced that Shawn M. Leland, PharmD, RPh, Elevation Oncology’s Founder and Chief Executive Officer, will present at the 40th Annual J.P. Morgan Healthcare Conference on Wednesday, January 12, 2022 at 9:45 a.m. ET, in a virtual format.

Enteris BioPharma, Inc. provided a review of its 2021 business achievements and development activities as the company anticipates growth opportunities during 2022 involving its industry-leading Peptelligence® and ProPerma® oral peptide and small molecule delivery technologies, and extensive pharmaceutical expertise.

Peptilogics today announced that the company received an award from the Cystic Fibrosis Foundation.

Exelixis, Inc. (Nasdaq: EXEL) today announced that enrollment is complete for CONTACT-03, the global, phase 3 pivotal trial evaluating the efficacy and safety of cabozantinib (CABOMETYX®).

Spectrum Pharmaceuticals today announced a strategic restructuring.

Genprex, Inc., a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes, announced its participation in upcoming investor and healthcare conferences to be held in January 2022.

bluebird bio to Present at the 40th Annual J.P. Morgan Healthcare Conference.